Biotech Values

[DewDiligence]

ABBV/ENTA—At 96%, the SAPHIRE-2 SVR rate is identical to the 96% SVR rate in SAPHIRE-1 (#msg-94169219) even though SAPHIRE-2 included only treatment-experienced patients of whom 49% were prior null responders. This is an impressive achievement!

On safety/tolerability, SAPHIRE-2 was no problem:

Discontinuations due to adverse events were reported in three [of 297] (1%) patients receiving the 3D regimen and no patients receiving placebo.

So, now it’s on to the PEARL-3 and PEARL-4 studies, which will determine whether ribavirin is needed in treatment-naïve GT1a and treatment-naïve Gt1b patients, respectively.